Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMINO BESTDOSE
2019-001837-15Phase 3Completed
- Sponsor
- CHU Nîmes
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of amikacin in septic shock and bacterial disease, sponsored by CHU Nîmes. Started May 2019; status: completed.
02
Drugs
amikacin
03
Conditions
septic shockbacterial disease
Beyond the preview
Go deeper on 2019-001837-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001837-15.